Kohei Ishiyama

Kohei Ishiyama

Auto-generated profile, based on publicly available information

Kohei Ishiyama

Hiroshima University, Department of Surgery, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TOTakashi Onoe
Takashi Onoe
MYMegumi Yamaguchi
Megumi Yamaguchi
TIToshimitsu Irei
Toshimitsu Irei
KIKohei Ishiyama
Kohei Ishiyama
TSTakeshi Sudo
Takeshi Sudo
HTHirotaka Tashiro
Hirotaka Tashiro

12 March 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
NINobuki Ishida
Nobuki Ishida
KIKohei Ishiyama
Kohei Ishiyama
YSYoshihiro Saeki
Yoshihiro Saeki
YTYuka Tanaka
Yuka Tanaka
HOHideki Ohdan
Hideki Ohdan
The activation of natural killer (NK) cells in the liver inhibits engraftment of intraportally transplanted islets. We attempted to modulate the activity of NK cells by co‐transplanting mesenchymal stem cells (MSCs) with islets in mice. We first investigated the ability of MSCs to secrete prostaglandin E2 (PGE2), a predominant inhibitor of NK cell function, in various combinations of inflammatory cytokines. Notably, we found that PGE2 production was partially delayed in MSCs activated by inflammatory cytokines in vitro, whereas liver NK cells were activated early after islet transplantation in vivo. Accordingly, pre‐activated MSCs, but not naive MSCs, substantially suppressed the expression of activation markers in liver NK cells after co‐transplantation with islets. Similarly, co‐transplantation with pre‐activated MSCs, but not naive MSCs, markedly improved the survival of islet grafts. These results highlight MSC co‐transplantation as an effective and clinically feasible method for enhancing engraftment efficiency.

5 November 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
Tomokazu KawaokaTomokazu Kawaoka
Tomokazu Kawaoka
STShoichi Takahashi
Shoichi Takahashi
YKYoshiiku Kawakami
Yoshiiku Kawakami
MTMasataka Tsuge
Masataka Tsuge
AHAkira Hiramatsu
Akira Hiramatsu
KCKazuaki Chayama
Kazuaki Chayama

31 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YSY. Saeki
Y. Saeki
KIK. Ishiyama
K. Ishiyama
NIN. Ishida
N. Ishida
YTY. Tanaka
Y. Tanaka
HOH. Ohdan
H. Ohdan
We previously demonstrated the pivotal role of natural killer (NK) cells in islet graft loss during the early phase after intraportal syngeneic islet transplantation (IT). Liver-resident DX5−NK cells were reported to possess memory-like properties, distinguishing them from conventional DX5+NK cells. Here, we investigated the impact of primary IT-induced liver DX5−NK cells on the engraftment of secondary-transplanted islets in mice. The culture of liver NK cells isolated from naive mice with TNF-α, IFN-γ, and IL-lβ, mimicking instant blood-mediated inflammatory reaction, led to significantly increased DX5−NK cell percentage among total liver NK cells. Consistently, the prolonged expansion of DX5−CD69+TRAIL+CXCR3+NK cells was observed after intraportal IT of 300 syngeneic islets (marginal mass). In most diabetic mice, 400 syngeneic islets of primary IT were sufficient to achieve normoglycaemia, whereas the same mass after secondary IT failed to induce normoglycaemia in mice that received 200 syngeneic islets during primary IT. These findings indicated that liver-resident DX5−NK cells significantly expanded even after syngeneic IT, and that these memory-like NK cells may target both originally engrafted and secondary-transplanted islets. Furthermore, anti-TNF-α treatment suppressed the expansion of liver-resident DX5−NK cells, resulting in successful islet engraftment after sequential ITs.

6 June 2012 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
HTHirotaka Tashiro
Hirotaka Tashiro
KIKentaro Ide
Kentaro Ide
HAHironobu Amano
Hironobu Amano
TKTsuyoshi Kobayashi
Tsuyoshi Kobayashi
TOTakashi Onoe
Takashi Onoe
HOHideki Ohdan
Hideki Ohdan

18 July 2018 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
FHFumihiro Hirata
Fumihiro Hirata
KIKohei Ishiyama
Kohei Ishiyama
YTYuka Tanaka
Yuka Tanaka
TKTsuyoshi Kobayashi
Tsuyoshi Kobayashi
MHMasakazu Hashimoto
Masakazu Hashimoto
H(Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)
Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)
Aim: We investigated the chemotherapy effect of resectable colorectal cancer with liver metastasis (CRLM) on the function of intrahepatic immune cells.Methods: We classified patients into adjuvant chemotherapy (bevacizumab+CapeOX) after hepatectomy group (group A) and neoadjuvant chemotherapy followed by hepatectomy group (group B), and collected peripheral blood mononuclear cells (PBMC) and liver mononuclear cells (LMNC) to ascertain phenotypic and functional differences.Results: There were no significant differences in lymphocyte fractions of either PBMC or LMNC between groups, except for the significantly lower percentage of natural killer (NK) cells in LMNC in group B than in group A. Significantly higher percentage of natural‐killer group 2, member D (NKG2D)‐ positive NK cells in PBMC and percentage of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐, NKp30‐, and signal regulatory protein β (SIRPβ)‐positive NK cells in LMNC were found in group B. Furthermore, significantly higher expressions of NKG2D and SIRPβ in peripheral blood NK cells and of NKp46 and CD122 in liver NK cells were found in group B. When LMNC were incubated with interleukin (IL)‐2 in vitro, no difference was observed in the expression of these molecules in NK cells between groups. Consistently, there was no difference in the cytotoxic activity of those LMNC against a colon adenocarcinoma cell line between groups.Conclusion: Colorectal cancer with liver metastasis patients treated with neoadjuvant chemotherapy showed enhanced expression of activation markers on peripheral blood and liver NK cells in comparison with patients who did not receive therapy; however, the difference in those function remains unclear. These results suggest that neoadjuvant chemotherapy does not have a negative impact on intrahepatic immune cells in resectable CRLM patients.